The association between circulating secreted protein acidic and rich in cysteine (SPARC) and glycosylated haemoglobin (HbA1c) during lifestylemodified weight reduction intervention in obese male subjects

Journal of International Medical Research

Volumn 39, Issue 2, 2011, Pages 528-532

  Kotani, K ^a   Yamada, T ^a   Taniguchi, N ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Body mass index; Glucose metabolism; Obesity; Osteonectin; Secreted protein acidic and rich in cysteine; SPARC; Weight loss

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; OSTEONECTIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INTERVENTION STUDY; JAPANESE; LIFESTYLE MODIFICATION; MALE; MEAN ARTERIAL PRESSURE; OBESITY; POSTPRANDIAL STATE; SEDENTARY LIFESTYLE; WEIGHT REDUCTION;

EID: 79955663121     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900221     Document Type: Article

References (13)

1. Sheard NF: Moderate changes in weight and physical activity can prevent or delay the development of type 2 diabetes mellitus in susceptible individuals. Nutr Rev 2003; 61: 76-79.
2. Aronne LJ, Isoldi KK: Overweight and obesity: key components of cardiometabolic risk. Clin Cornerstone 2007; 8: 29-37.
3. Tartare-Deckert S, Chavey C, Monthouel MN, et al: The matricellular protein SPARC/osteonectin as a newly identified factor up-regulated in obesity. J Biol Chem 2001; 276: 22231-22237.
4. Takahashi M, Nagaretani H, Funahashi T, et al: The expression of SPARC in adipose tissue and its increased plasma concentration in patients with coronary artery disease. Obes Res 2001; 9: 388-393.
5. Kanauchi M, Nishioka M, Dohi K: Secreted protein acidic and rich in cysteine (SPARC) in patients with diabetic nephropathy and tubulointerstitial injury. Diabetologia 2000; 43: 1076-1077.
6. Watanabe K, Okamoto F, Yokoo T, et al: SPARC is a major secretory gene expressed and involved in the development of proliferative diabetic retinopathy. J Atheroscler Thromb 2009; 16: 69-76.
7. Stolar M: Glycemic control and complications in type 2 diabetes mellitus. Am J Med 2010; 123(3 suppl): S3-S11.
8. Nesto RW, Nelinson DS, Pagotto U: Guiding clinical decisions on abdominal obesity and cardiometabolic risk. Clin Cornerstone 2009; 9: 43-54.
9. Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity: New criteria for 'obesity disease' in Japan. Circ J 2002; 66: 987-992.
10. Japan Atherosclerosis Society: Japan Atherosclerosis Society Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases. Tokyo: Japan Atherosclerosis Society, 2002 [in Japanese].
11. Scheen AJ, Paquot N, Letiexhe MR, et al: Glucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp studies. Int J Obes Relat Metab Disord 1995; 19(suppl 3): S14-S20.
12. Gerich JE: Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003; 163: 1306-1316.
13. Gong W, Yang Z, Ye W, et al: The association of dysglycaemia and cardiovascular disease in patients with metabolic syndrome. J Int Med Res 2009; 37: 1486-1492.